Related Experiment Video
Updated: Jul 2, 2025

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness
Published on: December 6, 2024
Generating Potential RET-Specific Inhibitors Using a Novel LSTM Encoder-Decoder Model
Lu Liu1, Xi Zhao1, Xuri Huang1
1Institute of Theoretical Chemistry, College of Chemistry, Jilin University, Changchun 130061, China.
Abstract:
The receptor tyrosine kinase RET (rearranged during transfection) plays a vital role in various cell signaling pathways and is a critical factor in the development of the nervous system. Abnormal activation of the RET kinase can lead to several cancers, including thyroid cancer and non-small-cell lung cancer. However, most RET kinase inhibitors are multi-kinase inhibitors. Therefore, the development of an effective RET-specific inhibitor continues to present a significant challenge. To address this issue, we built a molecular generation model based on fragment-based drug design (FBDD) and a long short-term memory (LSTM) encoder-decoder structure to generate receptor-specific molecules with novel scaffolds. Remarkably, our model was trained with a molecular assembly accuracy of 98.4%. Leveraging the pre-trained model, we rapidly generated a RET-specific-candidate active-molecule library by transfer learning. Virtual screening based on our molecular generation model was performed, combined with molecular dynamics simulation and binding energy calculation, to discover specific RET inhibitors, and five novel molecules were selected. Further analyses indicated that two of these molecules have good binding affinities and synthesizability, exhibiting high selectivity. Overall, this investigation demonstrates the capacity of our model to generate novel receptor-specific molecules and provides a rapid method to discover potential drugs.
Insights
Researchers developed a novel molecular generation model to create specific RET kinase inhibitors, addressing challenges with existing multi-kinase drugs. This AI-driven approach rapidly identifies promising drug candidates for cancer therapy.
Area of Science:
- Oncology
- Computational Chemistry
- Drug Discovery
Background:
- Receptor tyrosine kinase RET is crucial for nervous system development.
- Abnormal RET activation drives cancers like thyroid and non-small-cell lung cancer.
- Existing RET inhibitors are often multi-kinase, lacking specificity.
Purpose of the Study:
- To develop a novel molecular generation model for creating RET-specific inhibitors.
- To overcome limitations of current multi-kinase inhibitors.
- To accelerate the discovery of targeted cancer therapeutics.
Main Methods:
- Utilized fragment-based drug design (FBDD) and a long short-term memory (LSTM) encoder-decoder model.
- Trained the model for high molecular assembly accuracy (98.4%).
- Employed transfer learning to generate a RET-specific molecule library, followed by virtual screening, molecular dynamics, and binding energy calculations.
Main Results:
- Generated a library of RET-specific candidate molecules.
- Identified five novel RET inhibitor candidates.
- Two molecules demonstrated favorable binding affinities, synthesizability, and high selectivity.
Conclusions:
- The developed model effectively generates novel, receptor-specific molecules.
- This AI-driven approach offers a rapid and efficient method for discovering potential drug candidates.
- The identified molecules show promise as selective RET inhibitors for cancer treatment.
More Related Videos
07:57Direct Injection of a Lentiviral Vector Highlights Multiple Motor Pathways in the Rat Spinal Cord
Published on: March 15, 2019
12:13Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies
Published on: July 11, 2019
Related Concept Videos
LTR Retrotransposons
The internal coding region of LTR retrotransposons and their mechanism of transposition closely resembles a...
Conservative Site-specific Recombination and Phase Variation
The recognition sites for Cre recombinase called LoxP...